COLOPL Group Company Brilliantcrypto Inc., Reveals “Brilliantcrypto,” The Blockchain Game Which Generates Economic Value in The Metaverse With Digital World Gemstones
25.7.2023 08:00:00 EEST | Business Wire | Press release
The wholly owned subsidiary of COLOPL, Inc. (HQ: Minato City Tokyo; CEO: Takashi Miyamoto), Brilliantcrypto, Inc. (HQ: Minato City Tokyo; CEO: Naruatsu Baba), announced its new blockchain game “Brilliantcrypto,” which introduces the new “Proof of Gaming” concept at the global Web3 conference “WebX” (held on 25/07/2023).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724611315/en/
New blockchain game "Brilliantcrypto" (Graphic: Business Wire)
Game Overview
Brilliantcrypto is a blockchain game where players around the world become miners and excavate the mines with the aim of finding gemstones and tokens. Users buy pickaxes in the in-game marketplace, and use items like the “detector” while carrying out mining. By mining, players can obtain tokens and gemstones, and there will be the possibility to bring the gemstones, which can turn into NFTs, into many different metaverse worlds. There will also be the possibility to buy and sell the gemstones, as well as use them.
What is “Proof of Gaming”?
Simply put, “Proof of Gaming” is the game model version of “Proof of Work,” which is Bitcoin’s consensus algorithm.
In Bitcoin, mining is carried out in the form of a tremendous amount of hash calculations, which in turn guarantees value on the blockchain. Similarly, in Brilliantcrypto, mining will be carried out in the form of people throughout the world playing the game, which will guarantee the value of gemstones in the digital world.
Generating Economic Value In the Metaverse with “Proof of Gaming”
The metaverse is currently being developed, and we believe that one reason that could be given for it not fully catching on yet is that there is currently no “economic value.” If the value of digital world gemstones is guaranteed by “Proof of Gaming,” it becomes possible to use them not only in-game, but also in many different metaverse worlds, and so becomes possible to exchange them and use them. Therefore, the more exchanges begin to take place, the more the demand for gemstones with value will grow, and the more people from around the world will gather to play the game. We believe that through this cycle, “Proof of Gaming” will be activated further and as a result, true economic value will be generated in the metaverse.
Realizing Sustainable Play-to-Earn
In recent years, “play-to-earn,” which made it possible to earn money while playing games using a combination of blockchain technology and cryptocurrency, has been gathering global attention.
On the other hand, there has existed a sustainability issue with play-to-earn, as the system only allows individual, early adopters to actually make a profit. Through guaranteeing the value of digital world gemstones with Brilliantcrypto’s “Proof of Gaming” model, societal value will be generated and brought out into the world. That is why we believe sustainable play-to-earn can finally be made a reality.
About the Closed Beta Test
We will carry out a closed beta test before the official service launch.
Therefore, from today until Monday 08/08/2023 05:59 (UTC), we are accepting applications to participate in the beta.
Closed Beta Details
- Application Period: Tues. 25/07/2023 05:00 〜 Tues. 08/08/2023 05:59 (UTC)
- Amount of spots: Limited availability expected
- Beta Test Period:
1st Test: Tues. 15/08/2023 06:00 - Tues. 22/08/2023 05:59 (UTC)
2nd Test: Tues. 12/09/2023 06:00 - Tues. 19/09/2023 05:59 (UTC)
3rd Test: Tues. 10/10/2023 06:00 - Tues. 17/10/2023 05:59 (UTC)
- Clear Reward (1): Win ¥5000 worth of ETH (receivable by all who clear)
- Clear Reward (2): Enter a lottery, where 6 lucky players will win 2 VIP tickets to watch PSG play in France, in the tournament that decides the top European football team (return flight tickets included).
Closed Beta Application Page
https://beta-user-registration.brilliantcrypto.net
Game Website
https://brilliantcrypto.net
Social Media
- Twitter https://twitter.com/Brypto_Official
- Discord https://discord.gg/x23GWNu73B
- Youtube https://www.youtube.com/@Brilliantcrypto
Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724611315/en/
Contact information
Point of Contact regardings inquiries from the media on this release
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail:press.contact@brilliantcrypto.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
